Go to the list of all blogs
Alicia's Avatar
published in Blogs
Mar 20, 2026
Why Is Braskem S.A. (BAK) Stock Down -11.00% Today?

Why Is Braskem S.A. (BAK) Stock Down -11.00% Today?

Key Takeaways

  • BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer

  • The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​

  • Recent trading has also reflected fading optimism around M&A and restructuring narratives that previously supported the stock at higher levels​

  • Sector peers in Latin American chemicals and materials have faced pressure from slower global growth, volatile oil prices, and currency moves, weighing on sentiment​

  • Traders are watching for any balance sheet actions, guidance updates, and macro signals that could improve visibility on Braskem’s cash flow and debt trajectory

Opening Summary

Braskem S.A. (BAK) is a leading Latin American petrochemical and plastics producer, with operations spanning basic chemicals, resins, and biopolymers. In the most recent completed U.S. trading session, American depositary shares of BAK dropped about 11%, a significant move that pushed the stock further away from recent highs and closer to the lower end of its 12‑month trading range. The selloff follows a period of mounting pressure tied to elevated leverage, a weaker credit rating, and subdued petrochemical pricing, rather than a single headline catalyst on the day. The market reaction underscores renewed skepticism around the company’s ability to navigate a tougher cycle while managing its debt load.

Macro and Sector Headwinds Weigh on Sentiment

As a commodity-linked chemicals producer, Braskem’s earnings are highly sensitive to global demand, feedstock costs, and spreads in polyethylene and polypropylene markets. Recent data show petrochemical prices and margins under strain, reflecting slower industrial activity and uneven demand in key export markets. This backdrop has pressured cash generation at BAK, constraining the pace at which the company can reduce leverage. Investor sentiment toward cyclical chemicals has turned more cautious, with many reallocating to higher-visibility sectors as macro uncertainty persists. The latest 11% drop in BAK stock fits into this broader risk-off stance toward leveraged, cyclical names.

Credit and Balance Sheet Concerns

Credit quality remains a central overhang for BAK. S&P Global Ratings previously downgraded Braskem’s rating to BB from BB+, citing sustained high leverage and a negative outlook, and also cut ratings on its senior unsecured and subordinated notes. That downgrade reinforced concerns that the company has limited room for error if margins stay compressed or capital markets tighten. While management has signaled a commitment to deleveraging, investors appear unconvinced that internal cash flows alone can materially accelerate balance sheet repair in the near term. The latest slide suggests the market is re‑pricing the equity risk premium higher to reflect that credit profile.

M&A Narratives and Volatility

Braskem’s share price over the past year has often traded more on shifting M&A and strategic speculation than on steady fundamentals. Earlier stretches of strength were fueled by hopes for a transformative transaction or strategic sale that could unlock value and de‑risk the balance sheet. Those narratives have cooled as potential deals failed to materialize on terms equity investors expected, leaving BAK exposed to the underlying cyclical and credit story. Recent commentary notes that the stock has moved closer to its recent lows, with momentum traders stepping back while only selective value-oriented buyers remain interested on large down days. The 11% decline in the latest session thus reflects both fading deal hopes and thin liquidity amplifying downside moves.​

Market Context and Trading Activity

Trading data show that BAK has been volatile, with recent sessions seeing drawdowns approaching double digits over short windows and average daily volumes in the low‑ to mid‑hundred‑thousand share range. The most recent 11% drop occurred against a mixed broader market backdrop, where major U.S. indices were modestly changed and sector peers in chemicals saw milder moves, highlighting the stock‑specific nature of the decline. Technically, BAK has been trading well below prior peaks and has struggled to hold support zones identified around recent multi-month lows, reinforcing a bearish near‑term trend. With the price now sitting closer to its 52‑week bottom than its highs, some traders view it as a potential value play, while others see a value trap without clearer catalysts.

Trending AI Robots

For traders looking to navigate volatile names like BAK, Tickeron’s curated Trending AI Robots page highlights the platform’s strongest-performing AI-driven trading bots under current market conditions. Tickeron hosts hundreds of automated strategies that collectively cover thousands of tickers, but only a select subset with standout recent performance appears in this Trending section. These bots differ by strategy type, investment horizon, risk profile, and the symbols they trade, with transparent performance metrics to help users evaluate fit. Whether focusing on momentum, mean reversion, swing trading, or multi-factor models, the Trending AI Robots page offers a data-rich starting point for investors and active traders considering how to incorporate systematic tools into their decision-making.​

What Comes Next for BAK

Looking ahead, investors in BAK will focus on the company’s next earnings release and any updated guidance on volumes, spreads, and cash flow. Key questions include whether Braskem can accelerate deleveraging, pursue asset sales, or adjust capital spending to bolster its balance sheet in a still‑soft petrochemical cycle. Analyst expectations remain cautious, with credit metrics and free cash flow generation under particular scrutiny. Sector developments such as shifts in global polyethylene demand, changes in feedstock pricing, and Brazilian macro and currency trends will also influence the outlook. Until investors see firmer evidence of improving margins or a credible path to lower leverage, BAK is likely to remain sensitive to downside macro surprises and sentiment swings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BAK

Contributor

Alicia's AvatarAlicia|Beginner

BAK's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BAK turned positive on August 21, 2026. Looking at past instances where BAK's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BAK's RSI Oscillator exited the oversold zone, of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

BAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for BAK moved below the 200-day moving average on July 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BAK entered a downward trend on August 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (142.857) is very high in comparison to the industry average of (9.778). BAK has a moderately low P/E Ratio (0.000) as compared to the industry average of (33.814). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (20.317). BAK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.037). P/S Ratio (0.058) is also within normal values, averaging (1.454).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Dow (NYSE:DOW).

Industry description

The major diversified chemicals industry includes companies that produce a wide range of chemicals and industrial gases. The products are often used as raw materials in the manufacturing of various types of goods, including plastics, paints, carpets, and fixtures to name a few. Major companies making diversified chemicals include DuPont de Nemours Inc., Celanese Corporation, Celanese Corporation and Westlake Chemical Corporation.

Market Cap

The average market capitalization across the Chemicals: Major Diversified Industry is 2.65B. The market cap for tickers in the group ranges from 80.4K to 89.01B. SHECF holds the highest valuation in this group at 89.01B. The lowest valued company is DEVV at 80.4K.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Major Diversified Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -5%. LXU experienced the highest price growth at 9%, while TROX experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Major Diversified Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 38
Price Growth Rating: 60
SMR Rating: 88
Profit Risk Rating: 86
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
BAK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of petrochemicals and other related products

Industry ChemicalsMajorDiversified

Profile
Details
Industry
Chemicals Specialty
Address
Rua Lemos Monteiro
Phone
+55 1135769000
Employees
8668
Web
https://www.braskem.com.br
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
Why Is Braskem S.A. (BAK) Stock Down -11.00% Today?